CureVac Sees Unusually High Options Volume (NASDAQ:CVAC)

CureVac (NASDAQ:CVAC - Get Free Report) was the target of unusually large options trading activity on Thursday. Traders bought 1,936 call options on the stock. This represents an increase of 849% compared to the average daily volume of 204 call options.

CureVac Stock Down 0.5%

NASDAQ CVAC traded down $0.03 during trading on Friday, reaching $5.57. The company's stock had a trading volume of 4,834,011 shares, compared to its average volume of 800,115. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $1.25 billion, a PE ratio of 10.13 and a beta of 2.49. The business has a 50-day moving average price of $3.76 and a 200-day moving average price of $3.49. CureVac has a 1-year low of $2.37 and a 1-year high of $5.72.

CureVac (NASDAQ:CVAC - Get Free Report) last posted its earnings results on Thursday, May 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.08). The business had revenue of $0.94 million during the quarter, compared to analyst estimates of $4.27 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%. On average, research analysts forecast that CureVac will post 0.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CVAC has been the subject of several research reports. UBS Group decreased their price target on shares of CureVac from $13.00 to $12.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. JMP Securities restated a "market outperform" rating and set a $10.00 price target on shares of CureVac in a report on Wednesday, May 28th. Finally, Jefferies Financial Group reiterated a "hold" rating and issued a $5.00 target price (down from $7.00) on shares of CureVac in a research note on Friday.

Institutional Trading of CureVac

A number of institutional investors and hedge funds have recently modified their holdings of CVAC. Greenleaf Trust acquired a new stake in shares of CureVac in the first quarter worth $31,000. Integrated Wealth Concepts LLC lifted its stake in shares of CureVac by 25.0% in the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company's stock worth $42,000 after buying an additional 3,000 shares during the last quarter. Two Sigma Advisers LP acquired a new stake in shares of CureVac in the fourth quarter worth $48,000. Jump Financial LLC acquired a new stake in shares of CureVac in the fourth quarter worth $55,000. Finally, D. E. Shaw & Co. Inc. acquired a new stake in shares of CureVac in the fourth quarter worth $66,000. 17.26% of the stock is currently owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.